229 related articles for article (PubMed ID: 22212518)
21. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
[TBL] [Abstract][Full Text] [Related]
22. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients.
Rehman T; Fought J; Solomon R
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1610-4. PubMed ID: 18667743
[TBL] [Abstract][Full Text] [Related]
23. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
[TBL] [Abstract][Full Text] [Related]
24. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
25. Prediction of contrast-induced nephropathy in patients with serum creatinine levels in the upper normal range by cystatin C: a prospective study in 374 patients.
Wacker-Gußmann A; Bühren K; Schultheiss C; Braun SL; Page S; Saugel B; Schmid S; Mair S; Schoemig A; Schmid RM; Huber W
AJR Am J Roentgenol; 2014 Feb; 202(2):452-8. PubMed ID: 24450691
[TBL] [Abstract][Full Text] [Related]
26. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
27. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points.
Hoffmann U; Banas B; Fischereder M; Krämer BK
Kidney Blood Press Res; 2004; 27(3):161-6. PubMed ID: 15256811
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
[TBL] [Abstract][Full Text] [Related]
29. Effect of N-acetylcysteine on renal function in patients with chronic kidney disease.
Mainra R; Gallo K; Moist L
Nephrology (Carlton); 2007 Oct; 12(5):510-3. PubMed ID: 17803476
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of n-acetylcysteine in preventing contrast-induced nephropathy in type 2 diabetic patients without nephropathy.
Sar F; Saler T; Ecebay A; Saglam ZA; Ozturk S; Kazancioglu R
J Nephrol; 2010; 23(4):478-82. PubMed ID: 20383874
[TBL] [Abstract][Full Text] [Related]
31. 20-Hour preprocedural hydration is not superior to 5-hour preprocedural hydration in the prevention of contrast-induced increases in serum creatinine and cystatin C.
Torigoe K; Tamura A; Watanabe T; Kadota J
Int J Cardiol; 2013 Sep; 167(5):2200-3. PubMed ID: 22717305
[TBL] [Abstract][Full Text] [Related]
32. Preprocedure and Postprocedure Predictive Values of Serum β2-Microglobulin for Contrast-Induced Nephropathy in Patients Undergoing Coronary Computed Tomography Angiography: A Comparison With Creatinine-Based Parameters and Cystatin C.
Li S; Zheng Z; Tang X; Peng L; Luo Y; Dong R; Zhao Y; Liu J
J Comput Assist Tomogr; 2015; 39(6):969-74. PubMed ID: 26248154
[TBL] [Abstract][Full Text] [Related]
33. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
Poletti PA; Saudan P; Platon A; Mermillod B; Sautter AM; Vermeulen B; Sarasin FP; Becker CD; Martin PY
AJR Am J Roentgenol; 2007 Sep; 189(3):687-92. PubMed ID: 17715118
[TBL] [Abstract][Full Text] [Related]
34. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
[TBL] [Abstract][Full Text] [Related]
36. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
[TBL] [Abstract][Full Text] [Related]
37. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
[TBL] [Abstract][Full Text] [Related]
39. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department.
Kama A; Yılmaz S; Yaka E; Dervişoğlu E; Doğan NÖ; Erimşah E; Pekdemir M
Acad Emerg Med; 2014 Jun; 21(6):615-22. PubMed ID: 25039544
[TBL] [Abstract][Full Text] [Related]
40. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
